New stock news | Magnesium Excellence Shares Hong Kong IPO prospectus invalid
The Hong Kong IPO prospectus submitted by Magnesium Group Limited on June 30, 2025 expires after 6 months, on December 30, 2025. At the time of submission, China International Capital Corporation, Citigroup, and Deutsche Bank were its joint sponsors.
Magnesium Holdings Limited (referred to as Magnesium Holdings) submitted its Hong Kong stock prospectus on June 30, 2025, which expired after 6 months on December 30, 2025. CICC, Citigroup, and Deutsche Bank were its joint sponsors when submitting the prospectus.
The prospectus shows that Magnesium Holdings is an innovative leading automotive technology company dedicated to reshaping the future of mobility. The company focuses on the research and development of AI-driven integrated domain control solutions to help OEMs create the next generation of software-defined cars.
Although Magnesium Holdings currently focuses on the automotive sector, the technology and capabilities it has built, including modular software architecture and seamless integration of intelligent functions and hardware, are not only aimed at the progressive upgrade of traditional cars but also lay the groundwork for tomorrow's intelligent mobility and beyond.
Related Articles

New stock outlook | Accounts receivable accounts for more than 60% of revenue, how can Youlesai tell a good story of circular packaging?

"Zootopia 2" breaks box office records and tops the animated film box office champion of Walt Disney Company(DIS.US).

The new national medical insurance list will be implemented starting today, benefiting patients with three innovative drugs from SKB BIO-B (06990).
New stock outlook | Accounts receivable accounts for more than 60% of revenue, how can Youlesai tell a good story of circular packaging?

"Zootopia 2" breaks box office records and tops the animated film box office champion of Walt Disney Company(DIS.US).

The new national medical insurance list will be implemented starting today, benefiting patients with three innovative drugs from SKB BIO-B (06990).






